Open Access

Recombinant adeno-associated virus serotype 9 in a mouse model of atherosclerosis: Determination of the optimal expression time in vivo

  • Authors:
    • Qingjie Chen
    • Hui Zhai
    • Xiaomei Li
    • Yitong Ma
    • Bangdang Chen
    • Fen Liu
    • Hongmei Lai
    • Jia Xie
    • Chunhui He
    • Junyi Luo
    • Jing Gao
    • Yining Yang
  • View Affiliations

  • Published online on: February 22, 2017     https://doi.org/10.3892/mmr.2017.6235
  • Pages: 2090-2096
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Adeno-associated virus 9 (AAV9) has been identified as one of the optimal gene transduction carriers for gene therapy. The aim of the present study was to determine the gene transfection efficiency and safety of an AAV9 vector produced using a recombinant baculovirus (rBac)‑based system. AAV9‑cytomegalovirus (CMV)-green fluorescent protein was produced using an rBac system and the resulting vector particles were injected intravenously into mice. Animals were sacrificed at 14, 21, 28, 35, 60, 90 and 120 days following injection. GFP expression in aortic vasculature and aortic plaques in C57/6B and apolipoprotein E‑/‑ mice was analyzed by fluorescence imaging and western blotting. In vivo analyses of biological markers of liver and heart damage, and renal function, as well as in vitro terminal deoxynucleotidyl transferase dUTP nick end labeling analysis were used to determine the toxicity of the AAV9 carrier. The findings of the present study demonstrated that AAV9 viral vectors packaged using the rBac system functioned appropriately in arteriosclerosis plaques. The CMV promoter significantly induced GFP expression in the vascular plaque in a time-dependent manner. AAV9‑CMV viral particles did not lead to heart, liver or renal damage and no change in apoptotic rate was identified. These findings indicated that AAV9-CMV may be effectively and safely used to transfect genes into atherosclerotic plaques.

References

1 

Lewis SJ: Prevention and treatment of atherosclerosis: A practitioner's guide for 2008. Am J Med. 122(1 Suppl): S38–S50. 2009. View Article : Google Scholar : PubMed/NCBI

2 

De Nooijer R, Verkleij CJ, von der Thüsen JH, Jukema JW, van der Wall EE, van Berkel TJ, Baker AH and Biessen EA: Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 26:340–346. 2006. View Article : Google Scholar : PubMed/NCBI

3 

Zadelaar AS, von der Thüsen JH, Boesten LS, Hoeben RC, Kockx MM, Versnel MA, van Berkel TJ, Havekes LM, Biessen EA and van Vlijmen BJ: Increased vulnerability of pre-existing atherosclerosis in ApoE-deficient mice following adenovirus-mediated Fas ligand gene transfer. Atherosclerosis. 183:244–250. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Von Der Thüsen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ and Biessen EA: Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/− mice. FASEB J. 15:2730–2732. 2001.PubMed/NCBI

5 

White K, Büning H, Kritz A, Janicki H, McVey J, Perabo L, Murphy G, Odenthal M, Work LM, Hallek M, et al: Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther. 15:443–451. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Skubis-Zegadło J, Stachurska A and Małecki M: Vectrology of adeno-associated viruses (AAV). Med Wieku Rozwoj. 17:202–206. 2013.PubMed/NCBI

7 

Pacak CA and Byrne BJ: AAV vectors for cardiac gene transfer: Experimental tools and clinical opportunities. Mol Ther. 19:1582–1590. 2011. View Article : Google Scholar : PubMed/NCBI

8 

White SJ, Nicklin SA, Büning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M and Baker AH: Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 109:513–519. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Work LM, Büning H, Hunt E, Nicklin SA, Denby L, Britton N, Leike K, Odenthal M, Drebber U, Hallek M and Baker AH: Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther. 13:683–693. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF and Nienhuis AW: Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood. 97:1258–1265. 2001. View Article : Google Scholar : PubMed/NCBI

11 

Koeberl DD, Alexander IE, Halbert CL, Russell DW and Miller AD: Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA. 94:1426–1431. 1997. View Article : Google Scholar : PubMed/NCBI

12 

Aikawa R, Huggins GS and Snyder RO: Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction. J Biol Chem. 277:18979–18985. 2002. View Article : Google Scholar : PubMed/NCBI

13 

Prasad KM, Xu Y, Yang Z, Toufektsian MC, Berr SS and French BA: Topoisomerase inhibition accelerates gene expression after adeno-associated virus-mediated gene transfer to the mammalian heart. Mol Ther. 15:764–771. 2007. View Article : Google Scholar

14 

Bostick B, Ghosh A, Yue Y, Long C and Duan D: Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 14:1605–1609. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW and Chamberlain JS: Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 10:828–834. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA and Nakai H: Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol Ther. 14:45–53. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE, Zolotukhin I, Tarantal AF and Byrne BJ: Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 99:e3–e9. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J and Xiao X: Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 23:321–328. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Ghosh A, Yue Y, Long C, Bostick B and Duan D: Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. Mol Ther. 15:750–755. 2007. View Article : Google Scholar : PubMed/NCBI

20 

Pacak CA, Sakai Y, Thattaliyath BD, Mah CS and Byrne BJ: Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther. 6:132008. View Article : Google Scholar : PubMed/NCBI

21 

Chen BD, He CH, Chen XC, Pan S, Liu F, Ma X, Li XM, Gai MT, Tao J, Ma YT, et al: Targeting transgene to the heart and liver with AAV9 by different promoters. Clin Exp Pharmacol Physiol. 42:1108–1117. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Virag T, Cecchini S and Kotin RM: Producing recombinant adeno-associated virus in foster cells: Overcoming production limitations using a baculovirus-insect cell expression strategy. Hum Gene Ther. 20:807–817. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Chen H: Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol Ther. 16:924–930. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Chen H: Exploiting the intron-splicing mechanism of insect cells to produce viral vectors harboring toxic genes for suicide gene therapy. Mol Ther Nucleic Acids. 1:e572012. View Article : Google Scholar : PubMed/NCBI

25 

Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, Vetter R, Fechner H and Müller OJ: microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther. 18:199–209. 2011. View Article : Google Scholar : PubMed/NCBI

26 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

27 

Guo W, Wong S and Bhasin S: AAV-mediated administration of myostatin pro-peptide mutant in adult Ldlr null mice reduces diet-induced hepatosteatosis and arteriosclerosis. PLoS One. 8:e710172013. View Article : Google Scholar : PubMed/NCBI

28 

Foster K, Graham IR, Otto A, Foster H, Trollet C, Yaworsky PJ, Walsh FS, Bickham D, Curtin NA, Kawar SL, et al: Adeno-associated virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle. Rejuvenation Res. 12:85–94. 2009. View Article : Google Scholar : PubMed/NCBI

29 

Baker AH, Kritz A, Work LM and Nicklin SA: Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol. 90:27–31. 2005. View Article : Google Scholar : PubMed/NCBI

30 

Wang Z, Ma HI, Li J, Sun L, Zhang J and Xiao X: Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10:2105–2111. 2003. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2017
Volume 15 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, Q., Zhai, H., Li, X., Ma, Y., Chen, B., Liu, F. ... Yang, Y. (2017). Recombinant adeno-associated virus serotype 9 in a mouse model of atherosclerosis: Determination of the optimal expression time in vivo. Molecular Medicine Reports, 15, 2090-2096. https://doi.org/10.3892/mmr.2017.6235
MLA
Chen, Q., Zhai, H., Li, X., Ma, Y., Chen, B., Liu, F., Lai, H., Xie, J., He, C., Luo, J., Gao, J., Yang, Y."Recombinant adeno-associated virus serotype 9 in a mouse model of atherosclerosis: Determination of the optimal expression time in vivo". Molecular Medicine Reports 15.4 (2017): 2090-2096.
Chicago
Chen, Q., Zhai, H., Li, X., Ma, Y., Chen, B., Liu, F., Lai, H., Xie, J., He, C., Luo, J., Gao, J., Yang, Y."Recombinant adeno-associated virus serotype 9 in a mouse model of atherosclerosis: Determination of the optimal expression time in vivo". Molecular Medicine Reports 15, no. 4 (2017): 2090-2096. https://doi.org/10.3892/mmr.2017.6235